| Bioactivity | Apararenone (MT-3995) is a novel non-steroidal mineralocorticoid receptor antagonists under development for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis. | ||||||||||||
| Target | Mineralocorticoid receptor | ||||||||||||
| In Vivo | Recently, a phase II clinical trial has been initiated among patients with non-alcoholic steatohepatitis (NASH) in Japan[1]. | ||||||||||||
| Name | Apararenone | ||||||||||||
| CAS | 945966-46-1 | ||||||||||||
| Formula | C17H17FN2O4S | ||||||||||||
| Molar Mass | 364.39 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Kolkhof P, et al. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017 Jul;234(1):T125-T140. |
Apararenone
CAS: 945966-46-1 F: C17H17FN2O4S W: 364.39
Apararenone (MT-3995) is a novel non-steroidal mineralocorticoid receptor antagonists under development for the treatmen
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.